Evidence guide · NAD+ IV

NAD+ biology is established. IV outcomes need precision.

A claim-by-claim guide separating NAD+ mechanism, human evidence and what an IV clinic can responsibly promise.

For patients comparing the science and marketing claims around NAD+ IV therapy.

Clinical guide, not a prescriptionReviewed 22 August 2026How this page is governed

Indonesian nurse monitoring a patient during a supervised NAD+ infusion in a Bali villa — Supervised NAD+ care in Bali.

Mechanism is not an outcome

NAD+ participates in cellular redox reactions, energy metabolism, sirtuin signalling and PARP-related processes. Those roles explain biological plausibility; they do not establish that one infusion reverses ageing or guarantees more energy.

Human evidence is narrower

Human research on NAD metabolism is growing, but dose, route, population and endpoint matter. Evidence for oral precursors cannot simply be presented as proof of every intravenous claim.

The useful clinical question

The practical decision is whether a supervised session is suitable for this person, at this dose, for this objective, with clear expectations and follow-up.

How Clinic Terrain should communicate

State the dose, setting, duration, review process and uncertainty. Do not convert cellular mechanisms, testimonials or internal experience into guaranteed outcomes.

Connected clinical library

NAD+, from first question to monitored protocol.

Dose, duration, cost, evidence, tolerance and the clinical checks that connect them.

NAD+ therapy in Bali→NAD+ IV dose guide→NAD+ infusion duration→NAD+ cost in Bali→

Direct answers

Questions this evidence can, and cannot, answer.

Is NAD+ scientifically real?

Yes. NAD+ is a well-established biological cofactor. That is different from proving every commercial claim made for intravenous NAD+.

Does IV delivery guarantee a better result than oral precursors?

No guaranteed clinical result follows from route alone. Comparative outcome evidence, dose and individual context matter.

Evidence position

NAD+ biology is well established. Evidence for broad outcomes from intravenous NAD+ is still exploratory, so route, dose and expected benefit must be described separately.

Sources used for this page

Human studyGrant et al.: intravenous NAD+ metabolome pilot (2019) ↗Direct six-hour IV NAD+ administration and measured metabolic changes; a small pilot, not proof of broad clinical benefit.Human studyReal-world IV NAD+ and IV NR tolerability pilot (2026) ↗Exploratory infusion duration, symptoms and short-term biomarkers; retrospective data, not an efficacy trial.Scientific reviewVerdin: NAD+ in ageing, metabolism and neurodegeneration (2015) ↗Established NAD+ biology and mechanistic context; it does not establish outcomes from IV therapy.

Accountability

Who stands behind this clinical information.

01 · Editorial ownership

Clinic Terrain Clinical Editorial Team

Prepared and reviewed on 22 August 2026.

02 · Medical accountability

dr. I Wayan Cahyadi Surya Distira Putra, MPH

Clinic Terrain Chief Physician. He leads the medical interpretation of mechanistic, longevity, NAD+ and peptide pathways. The attending physician retains authority over the final clinical plan for each patient.

Chief Physician profile →

03 · Operating and publication standard

Klinik Pratama Cepat Sehat · Bali

Clinical editorial policy →Evidence library →

Your first message · Where you are + what you need help with

Turn what you have learned into a clear question for the clinical team.

Discuss NAD+ with the team →WhatsApp intake open 24/7 · One-minute first-response target